Clinical Trials for eFFECTOR Therapeutics

Explore 4 clinical trials worldwide

Showing 1-4 of 4 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: eFFECTOR Therapeutics

Clinical Trials (4)

Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

PHASE1Active, not recruiting

15 participants

Started: Sep 29, 2023 · Completed: Apr 23, 2030

1 condition3 sponsors1 location

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

PHASE2Active, not recruiting

68 participants

Started: Jun 2, 2021 · Completed: Dec 9, 2024

1 condition3 sponsors144 locations

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

PHASE1/PHASE2Recruiting

30 participants

Started: Oct 25, 2019 · Completed: Mar 31, 2025

1 condition1 sponsor14 locations

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

PHASE2Recruiting

180 participants

Started: Dec 24, 2018 · Completed: Aug 1, 2031

2 conditions4 sponsors3 locations